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Abstract: Insulin detemir is an analog of human insulin designed to provide a long duration 
of basal insulin action. This is achieved by protracted absorption from the injection depot, which 
results in part from increased self-association of insulin detemir molecules and in part from 
reversible albumin binding. Subsequent albumin binding in the circulation is thought to buffer 
changes in the effects at target tissues that could otherwise arise from variability in absorption 
rate. In consequence, insulin detemir has shown a less variable pharmacodynamic profile than 
alternative basal insulins; this manifests as more consistent temporal glucose reduction profiles 
in repeat-clamp studies. In clinical trials, insulin detemir has been characterized by consistent 
risk reductions in hypoglycemia, as well as reduced weight gain in comparison with other basal 
insulins. Given some recent associations that have been made in prospective and epidemiologic 
studies between glucose variability and/or hypoglycemia and increased cardiovascular risk, and 
the long-known association between excess weight and cardiovascular risk, it is possible that 
the clinical profile of insulin detemir may carry prognostic value with regard to cardiovascular 
safety, although this is yet to be substantiated. There have also been some concerns raised 
recently over the use of insulin analogs and cancer risk, but available clinical data and the 
receptor interaction profile of insulin detemir suggest no excess in risk in comparison with 
human insulin therapy. Optimal approaches for the clinical use of insulin detemir have been 
emerging through an increasing clinical study base, and the analog is becoming established as 
a potentially valuable therapy option.
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Introduction
Insulin therapy is fundamental in the treatment of type 1 diabetes, and there is a large 
consensus that its use should be optimized, taking advantage of new technologies such 
as rapid- and long-acting analogs (combined in basal-bolus regimens) and new devices 
for insulin delivery (such as insulin pumps) and continuous glucose monitoring. The 
objective is to mimic the natural dynamic patterns of insulin secretion to recreate as 
closely as possible the physiologic glucose regulation observed in nondiabetic patients, 
thereby preventing diabetic complications.1
Although the prevalence of type 1 diabetes appears to be relatively constant over 
time, that of type 2 diabetes is rising to pandemic levels, leading to an increased need 
for this condition to be managed in primary care. The range of treatments for type 2 
diabetes is growing, but insulins are usually required eventually. Primary care provid-
ers may find the complexity of choices available daunting, particularly the responsibility 
for initiating and advising on insulin injection therapy. A successful shift to primary 
care will require aid from specialist support.2Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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Although a sophisticated approach to insulin, including 
insulin analogs and delivery systems, is important in type 2 
diabetes, the association of this condition with insulin resis-
tance, overweight and other cardiovascular (CV) risk factors 
in the “metabolic syndrome” requires a multifaceted treat-
ment approach, likely to involve drugs designed to improve 
CV prognosis, such as antihypertensives, antiplatelet agents, 
lipid-lowering agents, and even appetite suppressants. Smok-
ing cessation, adapted diet, and physical activity are also key 
components of disease management. There is also a need for 
regular reassessment of treatment as the patient’s diabetes 
(and associated morbidity) progresses.3
This is all challenging enough, but making good treatment 
choices and advising upon this subject has been further 
complicated by new revelations about patient outcomes with 
well-established therapies. It was assumed until recently, 
based on landmark study data, eg, the UK Prospective 
  Diabetes Study (UKPDS) and Diabetes Control and Com-
plications Trial (DCCT), that patient prognosis would benefit 
from aggressive blood glucose reduction to levels as close 
to euglycemia as achievable. Thus, ambitious titration of 
insulin throughout the natural history of diabetes has been 
advocated. However, some recent studies, including the 
Action to Control Cardiovascular Risk in Diabetes 
(ACCORD),4 Action in Diabetes and Vascular Disease: 
Preterax and Diamicron MR Controlled Evaluation 
(ADVANCE)5 and Veterans Affairs Diabetes Trial (VADT),6 
designed to assess whether aggressive risk factor manage-
ment could improve CV prognosis in high-risk type 2 diabetes 
patients, raised concerns that overzealous blood glucose 
reduction might not be beneficial,7,8 with the ACCORD study 
suggesting a slight excess in CV mortality associated with 
intensive glucose reduction. This observation is not fully 
understood, but contrasts late follow-ups of the DCCT9 and 
UKPDS10 cohorts, where a CV disease (CVD) benefit 
emerged in patients originally assigned to more intensive 
glucose reduction, despite later convergence of HbA1c. It was 
therefore suggested that poor control early in the natural 
history of diabetes has a “legacy effect” (otherwise termed 
“metabolic memory”), whereby the contribution of hyperg-
lycemia to atherosclerotic processes is made early in the 
disease process, with macrovascular damage irreversible by 
later blood glucose reduction, which may even be harmful. 
It has been suggested that hypoglycemia might be the culprit 
that precipitates CV events in patients with established ath-
erosclerotic disease,11 although this hypothesis cannot explain 
with certainty the observations made in ACCORD/
ADVANCE, where other influences on CVD mortality may 
have applied, eg, pharmacologic actions/interactions of the 
therapies used, or the successful minimization of CV events 
by multiple risk factor management to rates at which glyce-
mic control has little influence.7,8 Subset analysis of recent 
landmark studies suggests that patients given intensive 
therapy before their diabetes becomes too advanced are most 
able to achieve good glycemic control, with a low rate of 
hypoglycemia and an improved long-term health prognosis.4–7 
However, a recent retrospective study highlighted the high 
risk of mortality observed in patients with low HbA1c levels.12 
Although interpretation remains difficult because of the study 
design and the lack of information on previous stages of 
diabetes, this study suggests that hypoglycemia could be 
highly deleterious and should be prevented.
Thus, a consensus is emerging that, alongside active 
management of other risk factors, good glycemic control 
must be established and maintained from diagnosis, with 
insulin initiated as soon as HbA1c levels begin to rise despite 
optimal use of antidiabetic drug therapies.1,7 In this setting, 
the low incidence of hypoglycemia incurred when modern 
insulin analogs are used13 also appears to be a particularly 
attractive property, with potential to limit CV risk.
Yet further uncertainty has recently arisen, however, fol-
lowing a series of studies that explored a putative link 
between the use of insulin glargine and cancer risk, all based 
on retrospective database analyses.14–17 While more reassur-
ing data have since been provided,18,19 these publications have 
increased awareness in the diabetes community of the link 
between diabetes, its treatments, and the risk of cancer.20 
Reassuringly, in this context, metformin is emerging as a 
therapy with potential benefits,21–23 but we may need to be 
mindful of potential differences between insulins.24
In the context of these new considerations, this review 
summarizes what we have learned about the safety and effi-
cacy of the basal insulin analog, insulin detemir (Levemir®, 
Novo Nordisk, Bagsværd, Denmark). As is the case for most 
glucose-lowering therapies, there are few data with which 
to evaluate the effect of insulin detemir directly on morbid 
outcomes over long-term treatment, so we must consider the 
surrogates usually measured in studies, such as blood glucose 
control, weight gain, biomarkers of CV risk, and hypogly-
cemia. This review also considers practical issues in the hope 
of advising on how to achieve the most favorable clinical 
outcomes when using insulin detemir.
A focus on insulin detemir is important because it is one 
of the candidates that can be used in a basal + oral regimen 
where, in type 2 diabetes, basal insulin is initiated simply by 
adding a once-daily injection to drug therapy. With   attention Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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to titration, this regimen achieves important improvements 
in glycemic control with a low risk of hypoglycemia,25 and 
is therefore an increasingly popular approach to insulin initia-
tion, especially in primary care. The strategy of initiating 
insulin with a basal rather than prandial or premixed regimen 
was recently reinforced by three-year follow-up data from 
the 4T study, in which patients starting insulin therapy with 
detemir achieved glycemic control after three years equiva-
lent to that of comparator regimens   (premixed- or bolus 
insulin-based), but had lower burdens of hypoglycemia and 
weight gain.26,27
Pharmacologic profile  
of insulin detemir
The basal insulin analogs were developed in response to the 
widely recognized limitations of traditional basal insulin 
formulations, such as neutral protamine Hagedorn (NPH) 
insulin, in which protamine is used to retard the absorption 
of subcutaneously injected human insulin. NPH insulin is 
characterized by a mean duration of action that falls well 
short of 24 hours, so it ideally requires twice-daily dosing. 
Perhaps more concerning is the fact that an injected dose of 
NPH insulin absorbs with a pronounced peak, the degree and 
exact timing of which can vary considerably between injec-
tions.28 This characteristic can precipitate hypoglycemia, 
with nocturnal events possible after evening injection. Noc-
turnal hypoglycemia is especially feared by patients, and will 
ultimately limit dose titration.
Another limitation of conventional insulin therapy is 
that subcutaneous injection is followed by absorption into 
the systemic circulation rather than direct delivery into the 
portal vein, as occurs with the natural pancreatic secretion 
of insulin. Only intraperitoneal delivery, using implanted 
pumps, for instance, could achieve a more physiologic 
insulin tissue distribution, but this technique remains 
experimental. This means that peripheral tissues are 
unavoidably overexposed to insulin relative to the liver, 
and this effect may contribute to the hypoglycemia and 
weight gain that often typifies insulin therapy,29 as elabo-
rated upon below.
The ideal basal insulin designed for subcutaneous 
  injection would have a flatter and longer time-action profile 
than that of NPH insulin. It might also be distributed so as 
to exert a more physiologic pattern of action across target 
tissues. In view of recent concerns about insulin and cancer 
risk, any analog of insulin developed to achieve the above 
goals would also need to have a profile of receptor interac-
tions that did not differ from human insulin.
Protraction principle  
and pharmacokinetic profile
In the pursuit of improved basal insulins, two different 
approaches have led to clinical success. The first, exemplified 
by insulin glargine, has been to modify the molecule to shift 
the isoelectric point.30 Insulin glargine features a single amino 
acid substitution at the terminal residue (A21) of the A chain, 
with two arginine residues also added to the B chain terminus 
(B31, 32). These modifications make the molecule soluble 
in acidic environments (as in the pharmaceutical formula-
tion), but it forms slowly absorbed precipitates in the neutral 
subcutaneous depot.
Insulin detemir has a very different protraction principle. 
There is deletion of the terminal B chain amino acid (B30), 
and a fatty acid side chain (myristic acid) is attached at B29 
(Figure 1). This region of the molecule was chosen because 
it is involved in self-association, but not in insulin receptor 
interaction.31 The change has the effect of enabling dihexa-
meric complexes to form in the injection depot, as well as 
enabling reversible albumin binding.32 Insulin detemir is 
thereby retained in the injection depot and, once absorbed, 
further albumin binding serves to retard it in the circulation 
and buffer the effect of any sudden changes in absorption 
rate.33 This property might explain the observation in 
  repeat-clamp studies that insulin detemir is characterized by 
  significantly lower within-subject variability in blood 
  glucose-lowering action from injection to injection compared 
with NPH insulin28 and insulin glargine.28,34
In many of the clinical studies performed before registra-
tion, insulin detemir was administrated twice daily (or else 
this option was available), so its duration of action was 
Figure 1 Molecular structure of insulin detemir.
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  commonly considered to be lower than that of insulin glargine, 
and insufficient to meet 24-hour basal insulin requirements 
from a once-daily injection regimen. For instance, whereas 
the duration of action of glargine was considered to be 
20–24 hours, the duration of action of detemir was reported 
to be 6–23 hours in a major treatment guideline publication.1 
However, the mean duration of action of insulin detemir in a 
clamp study in patients with insulin-treated type 2 diabetes 
(fasting C-peptide # 1 nmol/L) was identical to that of insulin 
glargine at clinically relevant doses (Figure 2).34 The relative 
blood glucose-lowering profiles of the two available basal 
insulin analogs have been reviewed in detail by Heise and 
Pieber,35 who have highlighted the importance of the within-
subject reproducibility of this profile from injection to injec-
tion. This aspect is discussed further below, but in terms of 
the mean time-action profile. Depending on the definitions 
used for beginning and end of action, the duration of effect of 
both detemir and glargine in clamp studies is about 24 hours.35 
Therefore, insulin detemir appears to be suitable for once-daily 
dosing in type 2 diabetes and once- or twice-daily dosing in 
type 1 diabetes, where glycemic control is critically dependent 
at all times on exogenous insulin supply.
While the basal insulin analogs are commonly described 
as having a long, flat, and peakless action, this should be 
considered with caution with reference to short-acting insu-
lin. As evident in Figure 2, their mean pharmacodynamic 
profile (following a single subcutaneous injection) is not 
totally flat, showing a slow increase in blood glucose- 
lowering action that reaches a maximum after about eight 
hours, before a gradual decline to baseline values at about 
24 hours. There is currently a paucity of data concerning how 
(or if) the glucose-lowering profile across 24 hours changes 
with repeated once- or twice-daily dosing.
A more physiologic tissue distribution?
A potentially unique feature of the pharmacology of insulin 
detemir is that its tissue distribution may be different from 
that of other exogenous insulins. This is evidenced by the 
consistent finding in clinical trials that insulin detemir 
causes less weight gain than other basal insulins,29,36 as 
discussed further below. The mechanism responsible for 
this observation remains unproven, but there are two main 
theories, both involving albumin binding. One idea is that, 
compared with traditional insulins, circulating detemir has 
relatively reduced access to peripheral tissues such as adi-
pose tissue as a result of albumin binding, whereas albumin-
bound detemir does have access to hepatocytes via the open 
endothelial fenestrae in hepatic sinusoids.29,37 As a result, 
more of the glucose-lowering effect of detemir (compared 
with other exogenous insulins) is accounted for by reduced 
hepatic glucose output as opposed to increased peripheral 
glucose uptake.37 This might imply that insulin detemir has 
a relatively reduced propensity for stimulating lipid storage 
in adipocytes, and implies a more physiologic gradient of 
action between the liver and periphery. A relatively greater 
effect of detemir on hepatic glucose output versus periph-
eral glucose uptake in comparison with NPH insulin was 
also demonstrated during enforced hypoglycemia; reassur-
ingly, counterregulatory responses and symptom awareness 
were fully preserved.38 The other theory advanced to 
account for the relative weight gain-sparing profile of 
detemir is that its albumin-binding properties result in an 
equilibrium across the blood-brain barrier whereby an 
increased proportion of unbound detemir in cerebrospinal 
fluid leads to   appetite-suppressing effects in the central 
nervous system and/or improved homeostasis of lipid 
metabolism.39–41
Figure 2 Mean 24-hour action profiles of three doses of insulin detemir and insulin glargine (A: 0.4 U/kg; B: 0.8 U/kg; C: 1.4 U/kg) in a glycemic clamp study in patients 
with insulin-requiring type 2 diabetes (fasting C-peptide concentration # 1 nmol/L). Reprinted from Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Albumin-
bound basal insulin analogues (insulin detemir and NN344): Comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab. 
2007;9:290–299.34 Copyright © 2007, with permission from John wiley and Sons.34
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Binding properties and molecular safety
As noted above, concerns have recently been raised about a 
possible association between insulin glargine and risk of 
cancer.14–17,20 This remains a debated issue following criticism 
of the methodology of some of these studies,42 and the failure 
of subsequent analyses of the insulin glargine database to 
identify any increased risk versus comparators.18,43 Neverthe-
less, the original investigation14 was undertaken based on the 
a priori hypothesis that insulin glargine might have increased 
mitogenic properties because it has been associated in some 
laboratory experiments and cell lines with increased affinity 
for the insulin-like growth factor I (IGF-I) receptor and/or 
increased mitogenicity compared with human insulin or other 
analogs.44–46 It is biologically plausible that insulin therapy 
could accelerate the development of existing subclinical 
tumors within timeframes of less than two years if these 
lesions express appropriate receptors.24 Insulin is a growth 
factor, and, as noted above, peripheral tissues may be exposed 
to supraphysiologic insulin levels when insulin is injected 
subcutaneously, especially at the high doses often used in 
type 2 diabetes. It is also possible that, while target tissues 
may be resistant to insulin in diabetes, neoplasms expressing 
insulin or IGF-I receptors may not be. Any risk could there-
fore potentially be increased if an insulin analog had receptor-
binding properties that were inadvertently and inappropriately 
modified. In fact, the only insulin analog shown to have 
tumor-promoting properties (at high doses) in an animal 
model was the early analog X10, and this was found to have 
increased residency at the insulin receptor as well as increased 
IGF-I receptor affinity.44,47 Insulin analogs possessing either 
of these two properties were shown to have increased mito-
genic properties in cell line studies.44
In the case of insulin detemir, the receptor-binding profile 
appears to be benign because insulin receptor residence time 
is actually reduced relative to human insulin, while the affin-
ity ratio for the insulin receptor:IGF-I receptor is fully pre-
served relative to human insulin.44 A retrospective analysis 
of the manufacturer’s clinical trials database showed a lower 
incidence of cancer associated with insulin detemir than NPH 
insulin (0.36 versus 0.92 events per 100 patient-years’ expo-
sure, P , 0.05), while there was a nonsignificantly lower 
incidence versus insulin glargine (0.87 versus 1.27, not 
statistically significant), albeit based on a very small dataset 
by epidemiologic study standards.19 The discrepancy in 
absolute event rate between these two comparisons probably 
reflects the fact that a higher percentage of the trials versus 
glargine were undertaken in type 2 diabetes.
Clinical efficacy and safety profile  
of insulin detemir
Glycemic control, variability, and risk  
of hypoglycemia
Insulin detemir has been subject to many clinical trials in 
type 148–59 and type 2 diabetes.60–67 The data are therefore far 
too numerous to discuss in detail in this review, but key 
endpoints and trial details are tabulated in Tables 1, 2, and 3 
and discussed here in more general terms. When assessing 
these clinical trial data, it is important to be aware of a couple 
of caveats. Firstly, trials of insulin detemir versus NPH 
insulin cannot be readily blinded because NPH is presented 
as a cloudy suspension that requires shaking before injection, 
whereas insulin detemir is presented as a clear solution. 
Therefore, the studies have employed open designs; however, 
the potential for bias is likely to be reduced by the fact that 
most of the endpoints assessed are objectively measured.
Glycemic control and trial design
Another important consideration is that, in order to ensure 
equivalence in insulin trials, it is customary to apply equal 
glycemic targets and/or titration algorithms. Moreover, trials 
are often designed to test noninferiority with regard to HbA1c 
as the primary endpoint. Consequently, unless tolerability 
becomes a significant barrier, equal levels of glycemic control 
are generally seen, meaning that differences between insulins 
are more often manifest in the secondary tolerability end-
points. This has been the general case in the insulin detemir 
trials program, but statistically significant advantages in 
glycemic control were obtained with insulin detemir versus 
NPH insulin in the longest trial (in type 1 diabetes) after two 
years, with this trial allowing continual dose titration.54 This 
might imply that the confidence to drive titration is gained 
over time with increasing familiarity, and thus further longer-
term research would be of interest.
Superior efficacy (as well as superior tolerability) was 
also obtained when insulin detemir combined in a basal + 
bolus regimen with insulin aspart was compared with an all 
human insulin basal + bolus regimen.53 This might seem an 
unfair comparison, but, as argued previously,68 basal analogs 
were originally designed for use in combination with rapid-
acting analogs, and because the short action of the latter often 
necessitates a compensatory increase in basal insulin dose, 
it may be that any advantages of the bolus analogs will be 
undermined by the imperfections of a basal insulin. Thus, an 
all-analog basal + bolus regimen allows both components to Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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be used to full advantage. Clearly, the results of the   Hermansen 
study53 (Table 3) show that a superior efficacy:tolerability 
ratio can be achieved with an analog regimen, at least in 
type 1 diabetes. The issues of how dosing frequency and 
titration protocols affect glycemic control are discussed 
below.
Glycemic variability: Prognostic 
importance often overlooked
One endpoint that has been included in the insulin detemir 
trials that had not been commonly assessed previously is 
intrasubject blood glucose variability. This follows the find-
ing in repeat-clamp studies of reduced variability of effect 
associated with insulin detemir versus NPH and glargine.28,69 
Glucose variability associated with insulin therapy is not 
easy to measure in ambulatory patients, so the rather crude 
surrogate of standard deviation in fasting glycemia has often 
been used. Nevertheless, as predicted from the clamp data, 
detemir was consistently associated with a reduction in this 
parameter compared with NPH insulin, and this was particu-
larly marked in type 1 diabetes (see Tables 1, 2, and 3). The 
apparent reduction in this advantage (and in absolute values 
for this parameter) in type 2 diabetes might relate to the effect 
of endogenous insulin-buffering differences between the 
exogenous insulin comparators. One study additionally 
assessed glucose variability in a subgroup using a continuous 
glucose monitoring system,52 and this again showed reduced 
variability with insulin detemir compared with NPH insulin 
(Figure 3).
Glycemic variability is often given little attention in daily 
clinical practice, but may be of prognostic importance. There 
is evidence that glucose variability, particularly when assessed 
by high postprandial glycemic excursions, adversely influ-
ences CV prognosis,70 highlighting the potential importance 
of insulin regimens and self-management programs that limit 
glycemic excursions and maintain glucose stability as effec-
tively as possible. Of course, basal insulins per se are not 
intended to curtail postprandial blood glucose rises effec-
tively, but a regimen that combines the reproducible basal 
insulin action of detemir with an intervention designed to 
achieve postprandial glucose control (eg, a rapid acting insulin 
analog) might be expected to benefit glycemic stability. Cur-
rent thinking is that glucose variability can lead to increased 
oxidative stress in type 2 diabetes,71 and adversely affect CV 
prognosis. An elegant study that illustrated this mechanism 
was provided by Ceriello et al.72 Here, blood glucose was 
clamped at two levels (10 and 15 mmol/L) and shown to result 
in concentration-dependent endothelial   dysfunction Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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(flow-mediated dilatation) and biomarkers of oxidative stress 
in both normal and type 2 diabetic subjects. When glucose 
was oscillated between 5 and 15 mmol/L every six hours for 
24 hours there were further significant increases in these 
parameters, above those seen even at a constant glucose level 
of 15 mmol/L. The effects of oscillating glucose, however, 
on both endothelial function and biomarkers of oxidative 
stress could be offset by administration of the antioxidant 
vitamin C. These data suggest that oscillating glucose might 
have more deleterious effects on CV function and prognosis 
than constant high glucose. This study (and hypothesis) is 
consistent with one by Monnier et al71 in which oxidative 
stress, assessed by urinary biomarkers, was shown in ambula-
tory patients with type 2 diabetes to be elevated versus healthy 
controls and to correlate with glucose variability.
An intriguing observation from the original landmark 
DCCT study was that the prognosis for microvascular mor-
bidity tended to be poorer with conventional versus intensive 
intervention at any given level of HbA1c, leading to the sug-
gestion that glucose variability could influence this morbidity 
too.73 Although this apparent observation may have been an 
artifact of statistical modelling,74 a recent analysis of DCCT 
data suggests that HbA1c variation adds to mean HbA1c in 
predicting incidence and progression of microvascular 
complications.75
So far, the studies discussed would support the argument 
that insulins causing less glycemic variability could carry an 
important long-term prognostic advantage. Interestingly, 
however, a recent analysis of biomarkers of oxidative stress 
in type 1 and type 2 diabetes patients has suggested that 
insulin therapy may limit (and even normalize) activation of 
oxidative stress (versus alternative drug therapies in type 2 
diabetes), regardless of the diurnal glycemic profile.70 More 
research is clearly required to elucidate fully the primary 
effects of glucose variability, and whether this remains of 
prognostic importance in insulin-treated patients. Neverthe-
less, it is worth highlighting that the differences in glucose 
variability observed between comparators in clamp and clini-
cal studies of insulin detemir imply that unstable glucose 
control is not entirely due to patient behaviors, and must at 
least partly reflect insulin kinetics.52
Hypoglycemia
One of the better known possible benefits of lower glucose 
variability is a reduced risk of hypoglycemia, and this has 
been another consistent finding with insulin detemir com-
pared with NPH insulin (Tables 1, 2, and 3). This is par-
ticularly true for nocturnal hypoglycemia, which is perhaps 
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weight gain
One of the most consistent findings across the insulin detemir 
clinical trials program was of reduced weight gain versus 
both NPH insulin and insulin glargine (Tables 1, 2, and 3). 
The mechanism responsible remains unclear, although two 
theories currently regarded as the most plausible are outlined 
above. In clinical trials in type 1 diabetes, insulin detemir has 
tended to be associated with unchanged weight, whereas other 
basal insulins have led to minor weight gain over the study 
periods. In type 2 diabetes trials, especially those where 
insulin is being initiated, insulin detemir has often been 
associated with a relative reduction of about 50% compared 
with alternative basal insulins (Table 3), and this advantage 
seems to be maximized when it is dosed once rather than 
twice daily.66,77 The absolute differences in weight gain 
between insulin detemir and comparators have been in the 
order of a just few kilograms over the study periods, but the 
relative advantage of detemir over NPH insulin has been 
found to increase with increasing baseline body mass index 
(BMI).61,78,79 Furthermore, the large-scale, open, observational 
PREDICTIVE study of the empiric use of detemir showed 
that patients switched from other basal insulins to detemir 
(within a basal-only therapy regimen) actually tended to lose 
weight (0.5–0.7 kg reduction, on average) despite improved 
glycemic control (HbA1c reduction 0.2–0.6%).80 Even more 
interesting was the finding that insulin-naïve patients initiated 
onto detemir in a basal insulin + oral antidiabetic drug (OAD) 
regimen in PREDICTIVE lost a mean 0.7 kg in weight despite 
a mean HbA1c reduction of 1.3%.81 Again, this apparent 
weight benefit increased with baseline BMI (Figure 3).
Type 2 diabetes is commonly causally associated with 
excess weight and sedentary lifestyle, and the resulting 
insulin resistance, so avoidance of further weight gain might 
actually facilitate disease management by delaying disease 
progression. Overweight is also an independent risk factor 
for CV disease, and it is associated with mortality risk in 
type 2 diabetes.82 Whether the avoidance of a small amount 
of weight gain with insulin detemir will translate into a 
meaningful risk reduction for CV events will be difficult to 
establish, but some analyses of epidemiologic data have 
suggested that even small gains in weight might lead to 
measurable increases in CV risk.82,83 Any prognostic signifi-
cance of the relative reduction in weight gain seen with 
insulin detemir is likely to reflect the nature of any relative 
change in body composition. This issue is currently under 
study, but data from a study in rodents suggest that much of 
the difference in weight gain seen between detemir and 
human insulin is accounted for by fat mass.84 Furthermore, 
Figure 3 weight change stratified by baseline body mass index in previously insulin-
naïve patients adding basal insulin to oral antidiabetic therapy. A) In a comparative 
treat-to-target trial. B) In the observational PREDICTIVE study. Figure 3a reprinted 
from Philis-Tsimikas A. Tolerability, safety and adherence to treatment with insulin 
detemir  injection  in  the  treatment  of  type  2  diabetes.  Patient  Prefer  Adherence. 
2008;2:323–332.79 Copyright 2008, with permission from Dove Medical Press Ltd. 
Figure 3b reprinted from Dornhorst A, Lüddeke HJ, Sreenan S, et al; PREDICTIVE 
Study Group. insulin detemir improves glycaemic control without weight gain in 
insulin-naïve patients with type 2 diabetes: Subgroup analysis from the PReDiCTive 
study. Int J Clin Pract. 2008;62:659–665.81 Copyright © 2008, with permission from 
John wiley & Sons, inc.
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not surprising given that basal insulins exert more control 
over nocturnal glycemia than daytime glycemia, which is 
also influenced by food consumption, exercise pattern, and 
the use of mealtime bolus insulins. The risk reduction for 
nocturnal hypoglycemia versus NPH in type 1 diabetes has 
been around 30%, with even greater relative risk reductions 
reported in type 2 diabetes.61,65 It is reassuring to note that 
this advantage extends to vulnerable patient groups, includ-
ing children and adolescents,58 and elderly populations.60
A recent analysis of data from the large observational 
PREDICTIVE™ study provided strong evidence that the 
reduced risk of nocturnal hypoglycemia seen with detemir is 
indeed causally related to reduced glycemic variability.76 
However, the reduced risk of nocturnal hypoglycemia reported 
for insulin detemir versus NPH (albeit from low absolute 
event numbers) in type 2 diabetes, in which glucose variability 
seems to be less of an issue, might involve a different mecha-
nism. One possibility is that the absorption profile of NPH 
insulin peaks earlier than that of insulin detemir, with the 
maximum glucose-lowering action occurring in the early 
hours of the morning following evening dosing.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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a study involving dual energy X-ray absorptiometry scanning 
of 14 insulin-treated patients randomized 1:1 to insulin 
detemir or NPH showed modest weight loss with detemir 
and weight gain with NPH (each of about 1 kg), with most 
of the difference in weight change accounted for by visceral 
fat.85 This is also supported by the observation of reduced 
waist circumference in patients switching to detemir from 
NPH insulin.86
It is also worth noting that patients may be tempted to 
compromise their glycemic control by deliberate underdosing 
of insulin as a tactic to avoid weight gain,87–89 and this behav-
ior is certainly likely to impact adversely both macro- and 
microvascular prognosis. Therefore, a relative reduction in 
weight gain could represent an important safety advantage 
for insulin detemir. A final point when considering the overall 
CV risk management of patients with type 2 diabetes is that 
the encouragement of weight loss is usually a core element 
of the treatment plan.77 Intervention often begins with diet 
and exercise, and progresses through the addition of treat-
ments chosen for their weight-sparing properties (eg, met-
formin, GLP-1 mimetics). This approach is informed by the 
need to reduce the patient’s CV risk, as well as to slow their 
diabetic disease progression. Insulin detemir therefore offers 
an option to continue rather than abandon this treatment 
philosophy at the point of insulin initiation.77
Hyperinsulinism
Whereas insulin is commonly dosed to achieve close to 
normal plasma levels in patients with type 1 diabetes, the 
higher doses usually necessary for patients with type 2 dia-
betes result in supraphysiologic plasma concentrations, 
which are necessary to compensate for insulin resistance. 
Indeed, hyperinsulinemia naturally occurs early in the type 2 
diabetes disease process as a compensatory response to tissue 
insulin resistance and, as such, is a common component in 
the metabolic syndrome, associated, albeit possibly indi-
rectly, with an increased risk of CV events.90,91 Therefore, it 
could be involved in the unexpected results observed in some 
of the outcome studies discussed above,4,5,12 which imply a 
failure to reduce CV complications despite improved glyce-
mic control. There are, however, confounding factors in these 
analyses, including the use of insulin secretagogue therapies 
(eg, sulfonylureas) and duration of diabetes. Hyperinsuline-
mia may also be involved in the occurrence of hypoglycemia 
and weight gain, while hyperstimulation of IGF-I receptors 
and other receptors might also increase the mitogenic risk.
Therefore, as far as possible, hyperinsulinemia should be 
prevented, despite the objective of lowering glycemic levels 
as close to normal as possible. This potential conflict high-
lights the importance of diet and exercise therapy as well as 
the use of drugs such as metformin, and possibly glitazones, 
which could theoretically limit insulin requirement.
Optimizing clinical success  
with insulin detemir
Overall, the clinical trials program suggests that insulin 
detemir can be used to achieve glycemic control that is at 
least equivalent to conventional basal insulins, but with a 
reduced burden of glucose variability, hypoglycemia, and 
weight gain. This profile is attractive, and has been sup-
ported by various analyses of PREDICTIVE,61,80,92–102 in 
which some 40,000 detemir-treated patients have been 
followed.
Most of the original clinical trials of insulin detemir car-
ried out in both type 1 and type 2 diabetes for registration 
purposes used twice-daily dosing regimens (comparing 
outcomes with twice-daily NPH insulin). This led many 
prescribers to regard insulin detemir as a basal insulin that 
should be given twice daily. In fact, critical reviews of out-
comes from basal insulin studies have concluded that twice-
daily dosing of a basal insulin, at least in type 2 diabetes, 
usually represents an inefficiency.25,77 It is important to realize 
that the duration of action of subcutaneously injected insulin 
is dose-proportionate,34,103 and that relatively high doses of 
basal insulin are administered in type 2 diabetes due to the 
tendency for patients to be heavy and insulin-resistant. As 
has been pointed out by Meneghini et al,77 even NPH insulin 
performs well in a once-daily regimen in this setting.104 With 
twice-daily administration, dose titration against two blood 
glucose target reading times becomes necessary (typically 
fasting and predinner), and this tends to escalate basal insulin 
dose without proportional improvement in glucose control.25 
This is because the total blood glucose-lowering effect of 
insulin is not simply proportional to the dose given, but is 
highly dependent on its rate of appearance in the circulation 
in relation to calorie intake.77 Thus, while the slow overnight 
absorption of exogenously administered basal insulin is a 
key determinant of fasting glycemia (and hence the baseline 
for glucose control during the daytime), the absorption of a 
basal insulin formulation will have relatively little impact on 
postprandial glucose rises, where a coordinated rapid rise in 
plasma insulin is needed to curtail the glucose excursion.106 
Furthermore, the advantage of less weight gain seen with 
insulin detemir over insulin glargine (given once daily) seems 
to be diminished in patients receiving detemir twice daily 
(and hence at higher doses).66 These observations support 
the view that the greatest efficiency (in terms of clinical Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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benefit:dose ratio) is achieved when detemir is dosed once 
daily in type 2 diabetes.
In type 1 diabetes, however, lower doses of insulin tend 
to be used (due to lower weight of patients and their greater 
insulin sensitivity) and glycemic control is more critically 
dependent on the minute-by-minute absorption of exogenous 
insulin. Given that the mean duration of action of therapeutic 
doses of the basal insulin analogs has been reported as close 
to (or, in some studies, slightly below 24 hours),35 at least 
some patients may benefit from their basal insulin being 
injected more frequently than once daily, as has been reported 
for insulin glargine.106,107 Therefore, the present author carried 
out a randomized comparative study (followed by an optional 
guideline-directed, nonrandomized, crossover phase) of 
once- versus twice-daily insulin detemir used as part of 
basal + bolus therapy in adult patients with type 1 diabetes.55 
The study showed moderate improvement of HbA1c after 
four months in patients randomized to both once-daily (before 
dinner) and twice-daily (before breakfast and dinner) detemir, 
with no significant difference between these groups in gly-
cemic control, despite a higher total insulin dose consumption 
associated with twice-daily detemir. Patients switching from 
once- to twice-daily detemir after four months showed no 
statistically significant improvement in HbA1c overall, but 
the few patients who switched from twice- to once-daily 
detemir showed a decline, which was apparently explained 
by the simple removal of the morning basal insulin injection 
without compensatory changes in other insulin doses. The 
study concluded that once-daily injection before dinner is 
the most efficient way to initiate detemir in adult type 1 
diabetes, although some individuals will benefit from twice-
daily dosing.
Interestingly, this hypothesis was tested retrospectively 
using 12-month data from the French cohort of the PREDIC-
TIVE study.108 Again, twice-daily dosing was found to be 
associated with no advantage in glycemic control despite 
higher dose consumption in the setting of basal + bolus-
treated type 1 and type 2 diabetes, and in basal + OAD-treated 
type 2 diabetes. However, it must be noted that this was not 
a randomized study, hence empiric choices regarding dose 
frequency were made.
The overall evidence outlined above suggests that optimal 
efficiency is obtained with once-daily insulin detemir for the 
majority of adult patients. Nevertheless, as can be seen in 
the data provided (Tables 1, 2, and 3), final HbA1c values 
have fallen short of guideline targets in most clinical studies, 
as is the case in most insulin trials generally. In type 1 dia-
betes, tight glycemic control is difficult to achieve, and most 
of the comparative studies have followed the classic protocol 
of switching previously insulin-treated patients to their 
  allocated study regimen, commenced with a short titration 
phase followed by a longer dose maintenance phase in which 
no further dose adjustment is made. In addition, most of the 
patients included in these controlled studies showed previ-
ously poor glycemic control, which was a criterion for inclu-
sion. It is therefore not surprising that glycemic control did 
not change substantially from baseline in many of these 
studies (Table 1) as there was no option to carry on adjusting 
dose beyond the titration phase, in which patients are often 
becoming accustomed to a new regimen. In this respect, it 
is noteworthy that the Hermansen et al53 study of analog 
versus human insulin basal + bolus regimens (Table 3) 
showed substantial improvement only in the analog arm, 
highlighting the importance of matching both basal and 
prandial insulin kinetics to physiologic need. Only recently 
has a continuous titration-to-target approach been applied in 
studies of insulin detemir in type 1 diabetes,54,59 and here the 
potential of insulin analogs to improve HbA1c becomes appar-
ent (Table 1).
The concept of continuous titration-to-target first emerged 
in type 2 diabetes following the publication by Riddle et al of 
a study designed to test whether addition of once-daily insulin 
glargine to OAD therapy as a simple approach to insulin 
initiation could achieve substantial improvements in glyce-
mia.104 The concept was validated and has been widely adopted 
subsequently, with several clinical studies of insulin detemir 
applying the concept successfully.61,65–67,97,109–111 A critical 
analysis of the type 2 diabetes titrate-to-target studies of 
insulin initiation with basal insulin has suggested that HbA1c 
improvement is typically in the order of 1.5% using this 
approach,25 but since this is independent of baseline control, 
it follows that satisfactory levels of control are typically only 
reached if basal insulin is initiated before HbA1c has risen to 
about 8.5%. Further studies have shown that patients can 
successfully manage goal-directed titration of insulin detemir 
themselves using simple algorithms such as the ‘303’ 
approach,77,97,109 in which the dose is adjusted by -3, 0 or +3 
units every three days, depending on the mean value of the 
previous three fasting plasma glucose (FPG) readings and/or 
occurrence of hypoglycemia. Such an algorithm may be 
particularly useful in primary care, and in terms of empower-
ing patients to manage their diabetes more effectively.
There has been some recent discussion about the appro-
priate FPG target against which to titrate the insulin detemir 
dose.77,109 Pharmacokinetic/pharmacodynamic comparisons 
with NPH insulin suggest, consistent with the lower risk of Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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nocturnal hypoglycemia reported in clinical trials, that insulin 
detemir typically has a later and smaller Cmax than NPH 
insulin. Following evening administration, this might coin-
cide with the time at which prebreakfast glucose readings 
for titration are taken. It is therefore possible that insulin 
detemir could be titrated using more ambitious FPG targets 
than would be tolerable for NPH insulin.77 This hypothesis 
implies that the full advantages of insulin detemir may not 
have been realized in the clinical trial program.
Indeed, the feasibility of using an extremely ambitious 
FPG target to tolerably achieve HbA1c , 7.0% with insulin 
detemir for patients with suboptimally controlled type 2 
diabetes was recently demonstrated in the TITRATE™ 
study.109 In this 20-week study, once-daily detemir therapy 
was added to the current OAD regimens in 244 insulin-naïve 
patients with type 2 diabetes, although dose reduction or 
discontinuation of sulfonylureas was permitted if patients 
were experiencing hypoglycemia. Patients were randomized 
into two groups, and each set a different FPG target, ie, either 
the classical 4.4–6.0 mmol/L or a lower target of 
3.5–5.0 mmol/L. The patients were taught how to self-titrate 
using the 3-0-3 algorithm described above. Thus, subjects in 
the 4.4–6.0 mmol/L target group adjusted the insulin dose 
by +3 units if their three-day mean FPG value was 
.6.1 mmol/L, and by -3 units if it was ,4.4 mmol/L (no 
adjustment if the mean value was within the target range). 
Similar 3-unit dose adjustments were made based on the 
lower FPG target at ,3.9 and .5.0 mmol/L. At the end of 
the study, 64.3% and 54.5% of subjects in the 3.9–5.0 and 
4.4–6.1 mmol/L groups, respectively, had achieved HbA1c 
levels , 7.0% (P  =  0.04, between groups). The 3.9–5.0 mmol/L 
group used slightly greater doses than the 4.4–6.1 mmol/L 
group (0.57 U/kg versus 0.51 U/kg at end of the study), and 
overall rates of hypoglycemia were low (7.73 and 
5.27 events/subject/year), with only one major hypoglycemic 
event reported (in the 3.9–5.0 mmol/L group).
Patient quality of life  
and treatment satisfaction
Compared with the data available for the hard endpoints 
assessed in the clinical trial program, there is a paucity of 
information with which to evaluate objectively the relative 
patient acceptability of insulin detemir. Intuitively, its 
reduced propensity for causing weight gain and low risk of 
hypoglycemia should translate into patient preferences, given 
that these are well-known patient concerns. Treatment 
  satisfaction should not be underestimated as an endpoint 
because this will ultimately affect adherence and uptake, and 
hence patient prognosis.112 Indeed, patient (and prescriber) 
resistance to the initiation of insulin therapy and nonadher-
ence to prescribed insulin injection regimens are documented 
problems.113–115 In this respect, modern injection devices, 
such as FlexPen® (Novo Nordisk, Bagsværd, Denmark), in 
which insulin detemir is presented, are known to facilitate 
patient acceptance,116 as well as dosing accuracy,117 
while insulin analogs in general are often reported to provide 
greater treatment satisfaction and adherence than compa-
rable human insulin-based formulations, presumably reflect-
ing their improved tolerability.118
A telephone-based survey of 586 insulin detemir users 
found that patients associated the drug with improved aware-
ness of blood glucose levels, increased confidence in glyce-
mic control, increased confidence in avoiding hypoglycemia, 
avoidance of weight gain, and improved satisfaction with 
treatment versus prior insulins.119 An analyses of a cohort of 
type 1 diabetes patients in Belgium who switched their basal 
insulin to insulin detemir in the PREDICTIVE study also 
reported a significant improvement in treatment satisfaction,120 
although it should be noted that this might have been a self-
selected group in which there had been atypically poor 
performance of previous insulin regimens.
Cost-effectiveness
Modern insulin analogs, including insulin detemir, have 
higher direct costs than conventional previous insulins, 
including NPH insulin. However, improvements in diabetes 
outcome and reductions in adverse events will lead to indirect 
cost reductions related to the management of diabetes and 
its complications, as well as potentially improving the life 
expectancy and quality of life of patients. It is therefore pos-
sible that analogs are cost-effective, although this can only 
really be tested in health economics models that make 
assumptions based on the trial data. It is noteworthy that 
several such analyses from different countries have suggested 
that insulin detemir is indeed cost-effective compared with 
conventional NPH insulin.121–124 In addition, analyses of the 
projected costs and benefits of converting patients poorly 
responsive to OADs or other basal insulins plus OADs to 
insulin detemir plus OADs have suggested that this will be 
a cost-effective therapy change.125,126
Conclusions and future perspectives
Subcutaneous insulin injection therapy will remain the 
mainstay of antihyperglycemic therapy for type 1 and advanc-
ing type 2 diabetes for the foreseeable future, and while new 
concerns have emerged about possible morbid outcomes with Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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certain agents or therapeutic approaches, there remains no 
doubt that diligent blood glucose control will positively affect 
both macro- and microvascular prognosis. To this end, the 
available evidence suggests that it is important to establish 
and maintain glycemic control as early as possible following 
diagnosis, to limit hypoglycemia, glycemic variability, and 
weight gain, and to manage other risk factors energetically, 
such as lipid profile, blood pressure and CV risk factors, 
including hyperinsulinemia. While, as is so often the case 
with individual pharmacologic agents, we lack direct evidence 
for the relative prognostic impact of insulin detemir, it does 
have a profile that appears attractive in the context of diabetes 
and risk management when compared with earlier basal 
insulins. It carries a low risk of hypoglycemia, is characterized 
by relatively low blood glucose variability, and relative avoid-
ance of weight gain, possibly reflecting a more physiologic 
pattern of tissue action than can be achieved with other sub-
cutaneously administered insulins.
This last point raises an issue in which we might expect to 
see future developments. The development and study of detemir 
and other analogs has shown that it might be possible to produce 
designer insulins that have a modified pattern of tissue distribu-
tion/action. It is certainly possible to produce insulin analogs 
which have receptor interaction profiles that differ from human 
insulin.24,44 Thus, while the preclinical development of insulin 
detemir originally focused on preserving the receptor-binding 
profile of human insulin (and the avoidance of increased mito-
genic potential will certainly continue to feature in the next 
generation of insulin analogs), it is possible that future analogs 
could be designed to have specific modified tissue or receptor 
actions. An understanding of how insulin detemir avoids the 
weight gain typical with other basal insulins might also inform 
future analog development.29 The next generation of basal 
insulin analogs, however, is likely to differ from today’s prod-
ucts primarily only in terms of kinetics. In development are 
some very long-acting basal insulins with the potential to be 
injected less frequently than once a day, and/or to achieve very 
flat and stable steady-state kinetics that should further benefit 
glycemic control and tolerability.
It is possible that refinements in the technology of exog-
enous insulin delivery will one day render subcutaneous 
injection (and hence even basal insulin products) obsolete. 
It is also possible that, as more becomes understood about 
the etiology of CVD in the setting of diabetes and blood 
glucose concentration, we might see significant modifications 
made to guideline treatment algorithms. In the meantime, 
however, we can expect to see a continuing increase in the 
use of basal insulin analogs as starter regimens in type 2 
diabetes and as standard components of basal + bolus insulin 
therapy. The clinical trial data suggest that analogs like 
insulin detemir are already improving glycemic control and/
or tolerability for many insulin dependent patients, and it is 
hoped that their prognoses will benefit accordingly.
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